ImmuneHuman RCT
LL-37: the body’s own antimicrobial peptide, and why the wound trials disappointed
LL-37 is central to innate immunity, but as a drug the evidence is thin: one small leg-ulcer trial looked good, and the larger follow-up failed.
LL-37
The only human cathelicidin, an antimicrobial peptide; topical wound trials were mixed and the largest, a 148-patient Phase 2b, failed.
- Also known as
- Cathelicidin, Cathelicidin LL-37, hCAP18 (precursor), CAMP
- Area
- Immune
- Status
- Not approved as a medicine; topical leg-ulcer Phase 2b missed its goal